|
|
|
|
|
文献清单:2024年高引文章鉴读|MDPI Antibodies |
|
|
期刊名:Antibodies
期刊主页:https://www.mdpi.com/journal/antibodies
本期编辑荐读为您精选2024年发表于 Antibodies 期刊的十篇高引文章。希望能为相关领域学者提供新的思路和参考,欢迎阅读。
1. Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
灾难性抗磷脂综合征的诊断和治疗以及2023年ACR/EULAR抗磷脂综合征分类标准的潜在影响
Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
https://www.mdpi.com/2073-4468/13/1/21
2. Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies
免疫介导性坏死性肌病(IMNM):抗体的故事
Sarah Julien, Inès Challier, Marine Malleter, Fabienne Jouen, Laurent Drouot and Olivier Boyer
https://www.mdpi.com/2073-4468/13/1/12
3. Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
PD-1、PD-L1、CTLA-4 和 LAG-3 免疫检查点抑制剂的不良事件:FDA 不良事件数据库分析
Connor Frey and Mahyar Etminan
https://www.mdpi.com/2073-4468/13/3/59
4. Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature
抗磷脂抗体与血液透析患者自体动静脉瘘并发症的关系:文献综述
Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier
https://www.mdpi.com/2073-4468/13/1/1
5. Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management
髓鞘少突胶质细胞糖蛋白抗体相关疾病:临床谱、发病机制和治疗管理的最新综述
Panagiotis Gklinos and Ruth Dobson
https://www.mdpi.com/2073-4468/13/2/43
6. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments
皮肤T细胞淋巴瘤CCR4疗法现状叙述性回顾:重点关注Mogamulizumab及未来疗法
Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri
https://www.mdpi.com/2073-4468/13/2/32
7. Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
银屑病治疗进展:从生物制剂到新兴口服小分子药物
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, Andrea Mangione, Chiara Dondi, Marta Del Vecchio, Veronica Carlevatti, Andrea Zovi, Maurizio Capuozzo and Roberto Langella
https://www.mdpi.com/2073-4468/13/3/76
8. Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature
揭秘GFAP星形胶质细胞病:案例研究的见解和全面的文献综述
Panagiotis Gklinos, Fotios Athanasopoulos, Vagia Giatrakou, Nikolaos-Achilleas Arkoudis, Dorothea Pournara, Eirini Giagkou, Argyro Tountopoulou, Sofia Vassilopoulou and Dimos-Dimitrios Mitsikostas
https://www.mdpi.com/2073-4468/13/4/79
9. SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination
SARS-CoV-2:感染和疫苗接种引发的先天免疫反应概览
Nicola Manfrini, Samuele Notarbartolo, Renata Grifantini and Elisa Pesce
https://www.mdpi.com/2073-4468/13/1/13
10. Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies
靶向生物制剂在眼内疾病治疗中的眼科应用:当前及新兴疗法
Yuan Zong, Miki Miyagaki, Mingming Yang, Jing Zhang, Yaru Zou, Kyoko Ohno-Matsui and Koju Kamoi
https://www.mdpi.com/2073-4468/13/4/86
Antibodies期刊介绍
主编:Arne Skerra, Technical University of Munich, Germany
期刊主题涵盖抗体和体液免疫反应、抗体的发现、产生和选择、抗体结构和功能、抗体工程、结合物和融合蛋白、生物医学研究和治疗中的抗体。
|
2024 Impact Factor
|
2.7
|
|
2024 CiteScore
|
4.5
|
|
Time to First Decision
|
22.2 Days
|
|
Acceptance to Publication
|
4.6 Days
|
特别声明:本文转载仅仅是出于传播信息的需要,并不意味着代表本网站观点或证实其内容的真实性;如其他媒体、网站或个人从本网站转载使用,须保留本网站注明的“来源”,并自负版权等法律责任;作者如果不希望被转载或者联系转载稿费等事宜,请与我们接洽。